Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sEphB4-HSA in Kaposi Sarcoma
NCT03993106Phase 2Recruiting
- Sponsor
- VasGene Therapeutics, Inc.
- Start
- Sep 2020
- Primary completion
- Dec 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of sephb4-hsa in Kaposi sarcoma (KS), sponsored by VasGene Therapeutics, Inc.. Started Sep 2020; status: recruiting.
02
Drugs
sephb4-hsa
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT03993106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03993106.